 Entasis Therapeutics Holdings Inc. ETTX Entasis, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the initial 3.3 million closing of a 35 million common stock and warrant securities investment 